---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-005194"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:48:14.360207+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Phio Pharmaceuticals appoints Robert Infarinato as CFO effective August 1, 2024

## Summary
- Robert M. Infarinato appointed VP & CFO effective August 1, 2024; will serve as principal financial and accounting officer.
- Mr. Infarinato, 78, is an attorney and CPA with over 20 years of financial leadership in pharma and biotech.
- Base salary $180,000; eligible for annual bonus up to 30% of base based on performance goals.
- Caitlin Kontulis ceased as principal accounting officer on August 1 and will leave employment on August 31, 2024.

## SEC filing metadata
- accession: 0001683168-24-005194
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316824005194/0001683168-24-005194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316824005194/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-005194
- JSON: https://secwatch.observer/filing/0001683168-24-005194.json
- Plain text: https://secwatch.observer/filing/0001683168-24-005194.txt

## Key facts
- Executive change
  Caitlin Kontulis departed as Vice President of Finance and Administration and Secretary at Phio Pharmaceuticals Corp..
  - Action: ceased serving
  - Role: Vice President of Finance and Administration and Secretary
  source text: Caitlin Kontulis, Vice President of Finance and Administration and Secretary of the Company, ceased serving as the Company’s principal accounting officer, effective as of August 1, 2024, with her employment terminating on August 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533040/000168316824005194/0001683168-24-005194-index.htm
- Executive change
  Robert M. Infarinato was appointed as Vice President, Chief Financial Officer at Phio Pharmaceuticals Corp..
  - Action: appointed
  - Role: Vice President, Chief Financial Officer
  source text: On July 15, 2024, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) approved the appointment of Robert M. Infarinato to serve as the Company’s Vice President, Chief Financial Officer and designated him as the Company’s principal financial officer and principal accounting officer, effective as of August 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533040/000168316824005194/0001683168-24-005194-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.